Gaku Nakazawa

Kindai University Hospital
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Background Preprocedural screening using transesophageal echocardiography (TEE) and computed tomography (CT) is widely performed in patients undergoing left atrial appendage (LAA) closure (LAAC). However, established methods for accurately predicting procedural device success (DS) remain unclear. Aims This study aimed to evaluate whether a novel preprocedural CT‐based assessment focusing on the landing zone and presence of an internal septum could improve DS prediction. Methods We analyzed 560 patients from a Japanese multicenter registry who underwent LAAC with Watchman FLX (Boston Scientific, USA). Preprocedural CT multiplanar reconstruction measured the diameter of the LAA landing zone (Dland), LAA length (L), and major lobe ostium diameter (Dlobe), if present. Based on these measurements, a ratio calculation (Rcal), defined as L/(Dland−Dlobe), was used to predict DS. The predictive performance of this ratio was evaluated using receiver operating characteristic (ROC) curve analysis and compared with that of conventional CT‐ and TEE‐derived depth‐to‐ostium ratios. Results DS was achieved in 95.5% (535/560) of patients. The mean Rcal was significantly lower in the failure group than in the success group (0.66 ± 0.25 vs. 1.00 ± 0.28; p < 0.001). Rcal predicted DS with an area under the ROC curve (AUC) of 0.872 ( p < 0.001). An optimal Rcal cutoff of 0.77 demonstrated 80.0% sensitivity and 83.4% specificity. Rcal showed superior predictive performance compared with CT depth/ostium ratio (AUC: 0.552) and TEE depth/ostium ratio (AUC: 0.456). Conclusions The novel CT‐derived metric, Rcal, which accounts for LAA landing zone dimensions and internal septa, predicts the DS of Watchman FLX. Rcal may improve pre‐LAAC patient selection and procedural planning.

Year:

2026

Aims Residual mitral regurgitation (MR) after mitral transcatheter edge-to-edge repair (M-TEER) is associated with adverse prognosis. However, the long-term clinical impact of MR persistence or progression has not been well stratified. We aimed to evaluate the proportion, clinical benefits, and prognostic value of maintaining mild MR one year after M-TEER. Methods and Results This multicenter registry-based analysis included 1,865 patients who achieved mild MR at discharge following M-TEER. At one year, patients were classified as having stable MR (≤ mild) or worsening MR (≥ moderate). The frequency of left atrial (LA) and left ventricular (LV) reverse remodeling and tricuspid regurgitation (TR) improvement were assessed from baseline to one year. Clinical endpoints—including all-cause mortality and heart failure hospitalization—were evaluated beyond one year after M-TEER up to two years. Worsening MR occurred in 28.4% of patients. Compared with the worsening MR group, the stable MR group demonstrated significantly more frequent LA and LV reverse remodeling (38.4% vs. 28.1%, and 44.7% vs. 31.1%, respectively; both p<0.001). Improvement in TR (≥ grade 1) was also more prevalent in the stable MR group (32.4% vs. 20.6%, p<0.001). Worsening MR was independently associated with increased risk of adverse clinical outcomes (hazard ratio: 2.02; 95% confidence interval: 1.26–3.23; p=0.003). Conclusions Maintaining MR within mild at one-year post-M-TEER is associated with favorable cardiac reverse remodeling and improved clinical prognosis. These findings underscore the importance of long-term MR surveillance and its implications for outcome optimization following M-TEER.

Year:

2026

Background Combination therapy with atherectomy and intravascular lithotripsy (IVL) has emerged as a promising strategy for the treatment of severely calcified occlusive coronary lesions, which potentially enhances procedural efficacy without increasing complication risk. Methods The Dual-Prep Registry is a multicenter, prospective registry designed to evaluate the safety and efficacy of IVL after atherectomy in severely calcified lesions. Combined use was selectively applied when the risk of complications was anticipated to be high with a larger atherectomy burr size, or when it was deemed non-beneficial due to unfavorable guidewire bias. All adverse events were adjudicated by a clinical events committee. Kaplan-Meier analysis was performed to evaluate the primary endpoint of major adverse cardiovascular events (MACE; composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization [TVR]) at 1 year. Results A total of 118 cases (120 lesions) were enrolled across 20 facilities. Significant comorbidities included diabetes in 56.8% of patients and hemodialysis-dependence in 25.4%. Calcification score after atherectomy was 4.0 in all cases, and calcified nodules were present in 56.4% (core-lab analysis) of cases. One-year follow-up was complete in 99.2% patients. MACE occurred in 7.6% patients at one year (cardiac death 2.5%, myocardial infarction 5.1%, TVR 5.1%) and stent thrombosis was observed in 1 case. Conclusions Atherectomy followed by IVL resulted in low 1-year rates of MACE, TVR, and stent thrombosis in patients with severely calcified coronary lesions. This approach may be considered for lesions where an “IVL-first” strategy is difficult to apply. Japan Registry of Clinical Trials: jRCT1032230384. URL: https://jrct.mhlw.go.jp A Clinical Perspective 1) What Is New? Elective combined use of IVL and atherectomy resulted in low 1 year MACE and TLR. The incidence of MACE was higher in cases with greater residual stenosis after the procedure and a larger baseline reference vessel diameter. 2) What Are the Clinical Implications? Combining IVL with atherectomy may serve as an effective treatment strategy in cases where IVL-first approaches are difficult to apply. Severe calcified lesions that are presumed to be unresponsive to RA/OA treatment or carry a high risk of RA/OA complications may be good candidates for this strategy.

Year:

2025

Background Anticoagulants are often less frequently prescribed in elderly patients with atrial fibrillation (AF) because of concerns regarding high bleeding risk, despite their increased susceptibility to embolic stroke and systemic embolization. This study evaluated the impact of the Clinical Frailty Scale (CFS) on clinical outcomes and decision-making for prescribing antithrombotic therapy following left atrial appendage closure (LAAC) in a large contemporary registry. Methods The OCEAN-LAAC registry included 1,409 patients who underwent LAAC. Outcomes and antithrombotic prescriptions after the procedure were compared between groups stratified by CFS into 1–3 and 4–8. Results Patients with CFS 4–8 were more likely to have a history of stroke and demonstrated lower serum albumin and hemoglobin levels, consistent with advanced frailty. In multivariate analysis, CFS 4–8 was independently associated with higher all-cause mortality at one year compared with CFS 1–3 (adjusted hazard ratio 1.89; 95% confidence interval 1.05–3.41). By one year, patients with CFS 4–8 more frequently discontinued antithrombotic therapy, without significant differences in ischemic stroke or device-related thrombotic events. Notably, major bleeding was more common in the CFS 4–8 group, reflecting their advanced clinical vulnerability. Conclusion Greater frailty, as assessed by CFS, was independently associated with increased all-cause mortality following LAAC. Although frailty influenced patterns of antithrombotic therapy in this real-world registry, thrombotic events remained comparable between CFS groups, supporting the feasibility of individualized, frailty-guided post-LAAC management. These findings underscore the importance of incorporating frailty assessment into multidisciplinary Brain–Heart team decision-making.

Year:

2025

Background One‐year clinical and hemodynamic outcomes after transcatheter aortic valve replacement (TAVR) using the latest generation balloon‐expandable valve (BEV) and self‐expandable valve (SEV) is not well understood. This study is aimed to compare 1‐year morality and hemodynamics between the latest generation BEV and SEV after TAVR. Methods We retrospectively analyzed 1393 patients undergoing TAVR using BEV (63.7%) (SAPIEN3 Ultra RESILIA) and SEV (36.3%) (Evolut FX). The incidence of all‐cause mortality and bioprosthetic valve dysfunction (BVD) over 1‐year were compared between BEV and SEV in both overall and propensity score (PS) matched cohort. Results During 1‐year follow‐up, the incidence of all‐cause mortality was comparable between BEV and SEV in the overall (10.8% vs. 8.0%, log‐rank p = 0.30) and PS matched cohort (11.0% vs. 8.9%, log‐rank p = 0.40). The incidence of BVD through 1‐year was also comparable between BEV and SEV in the overall (6.2% vs. 6.9%, p = 0.59) and PS matched cohort (6.7% vs. 8.2%, p = 0.55). Of BVD component, post‐procedural mean pressure gradient more than 20mmH was higher in BEV, while para‐valvular leakage more than moderate was higher in SEV. There was non‐linear relationship between annulus size and BVD, in which TAVR with BEV had higher BVD in a small annulus, while SEV had higher BVD in a large annulus. Conclusions In TAVR using the latest generation valves, incidences of mortality and valve performance during 1‐year were comparable between BEV and SEV. Whereas, the impact of annulus size on the difference of valve hemodynamics between BEV and SEV is still observed.

Year:

2025

Aims In patients with ventricular functional mitral regurgitation (VFMR) undergoing transcatheter edge-to-edge repair (M-TEER), the prognostic significance of the ratio between mitral regurgitant volume and left atrial volume (LAV) remains unclear. This ratio may reflect the proportional or disproportionate burden of regurgitation on the left atrium. To address this gap, we aimed to investigate the association between the regurgitant volume (RVol)/LAV ratio and clinical outcomes in patients with VFMR, using data from a multicentre prospective registry. Methods and results We calculated the RVol/LAV ratio from baseline transthoracic echocardiograms. The median value of the RVol/LAV ratio was 0.40. A total of 1830 patients who underwent M-TEER were allocated into two groups: the low RVol/LAV (RVol/LAV ratio <0.40) and high RVol/LAV (RVol/LAV ratio ≥0.40) groups. The primary endpoint was heart failure hospitalization. Eight hundred eighty-eight and 942 patients were included into the low RVol/LAV ratio and high RVol/LAV ratio groups, respectively. The median follow-up period was 508 days. At 3 years after repair, 215 (37.6%) and 187 (32.1%) patients in the low RVol/LAV and high RVol/LAV groups, respectively, were hospitalized for heart failure. The patients in the low RVol/LAV group demonstrated a significantly higher risk of heart failure hospitalization than did those in the high RVol/LAV group (hazards ratio, 1.25; 95% confidence interval, 1.03–1.52; P = 0.022). Furthermore, using multivariable Cox regression analysis, the low RVol/LAV was an independent predictor of the primary endpoint. Conclusion The RVol/LAV ratio might serve as a valuable metric for improving risk stratification in patients with VFMR. Clinical trials OCEAN Mitral registry (UMIN ID: UMIN000023653)

Year:

2025

Background Tricuspid regurgitation is a prevalent condition among patients with heart failure. Functional tricuspid regurgitation arises from multiple contributing factors, and tricuspid regurgitation severity is sensitive to changes in volume status. Importantly, significant tricuspid regurgitation is associated with adverse outcomes; therefore, tricuspid regurgitation management is crucial. Case summary We describe the case of a 92-year-old man was diagnosed with decompensated heart failure with underlying reduced ejection fraction, multivessel coronary artery disease, low-flow low-gradient aortic stenosis, atrial flutter, and severe tricuspid regurgitation without leaflet coaptation. Owing to the high surgical risk, a minimally invasive treatment strategy was adopted. The patient underwent percutaneous coronary intervention of the left coronary artery, including the left main coronary artery, after which sinus rhythm was spontaneously restored. However, the severity of tricuspid regurgitation remained unchanged posttreatment. Thus, transcatheter aortic valve implantation was subsequently performed. Remarkably, echocardiography on the day after transcatheter aortic valve implantation revealed an improvement in tricuspid regurgitation severity from severe to moderate, with leaflet coaptation and size reduction of the right atrium and right ventricle. Discussion This case highlights that severe tricuspid regurgitation, even without leaflet coaptation, can be improved through comprehensive management of ischaemia, valvular heart disease, and arrhythmia in the absence of surgical treatment. This treatment approach may offer clinical benefits to patients at high surgical risk.

Year:

2025

Background The association of outcomes with initial clip selection has not been investigated in patients undergoing transcatheter edge‐to‐edge repair with the MitraClip G4. Methods We analyzed 2257 patients receiving the MitraClip G4 according to the initial clip type: short (NT/NTW) versus long (XT/XTW) and narrow (NT/XT) versus wide (NTW/XTW). We performed a propensity‐matched analysis of baseline anatomical features in patients with primary and secondary mitral regurgitation (MR). Results The proportions of the initial clip types were as follows: NT, 18.9%; NTW, 41.7%; XT, 5.1%; and XTW, 34.3%. The proportions of the MR severity ≤1+ at discharge and 1 year were not significantly different among the 4 clip types. The incidence of death or heart failure hospitalization was not significantly different between the initial long and short clip groups and between the initial wide and narrow clip groups. After propensity matching, in patients with primary MR, long clips were significantly associated with a greater MR reduction (2.87±0.89 versus 2.62±0.99, P =0.04) and a higher proportion of the MR severity ≤1+ at 1 year (68.2% versus 48.6%, P =0.04) than short clips. In patients with secondary MR, long or wide clips had a similar MR severity at discharge and 1 year as short or narrow clips. Conclusions Residual MR severity and outcomes were not different regardless of the initial clip type, indicating the optimal clip selection in the real‐world settings with the MitraClip G4. In patients with primary MR, greater and more durable MR reduction may be expected by using the initial long clips. Registration URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN‐ID: UMIN000023653.

Year:

2025

Background Ensuring coronary access is essential for lifetime management after transcatheter aortic valve replacement (TAVR). However, the data on coronary alignment using the latest supra‐annular (SA) and intra‐annular (IA) self‐expandable valves (SEV) are limited. Aims This study evaluated coronary alignment after TAVR using SA‐SEV and IA‐SEV using post‐procedural CT images. Methods This retrospective study analyzed TAVR cases using the latest SA‐SEV ( n = 250) and IA‐SEV ( n = 152). Coronary overlap (CO) was assessed by measuring the angle between the neo‐commissure and coronary ostium. Coronary geometry was evaluated by the vertical distance from the coronary ostium to top of the outer skirt and the horizontal distance from the ostium to the transcatheter heart valve (THV) frame. Results The SA‐SEV was associated with significantly lower rates of severe CO than the IA‐SEV in both the left (LCA) (10% vs. 42%) and right coronary arteries (RCA) (12% vs. 34%). The vertical distance from the coronary ostium to the outer skirt was shorter in SA‐SEV than in IA‐SEV for both arteries (LCA: 3.3 mm vs. 8.0 mm; RCA: 4.4 mm vs. 9.0 mm). Conversely, SA‐SEV demonstrated a wider horizontal distance between the coronary ostium and THV frame than IA‐SEV (LCA: 4.8 mm vs. 3.8 mm; RCA: 5.4 mm vs. 4.4 mm). Conclusions CO and ostial geometry relative to the THV frame differed significantly between the two SEV platforms. Balancing these anatomic and device‐specific factors may be essential to ensure future coronary access following TAVR.

Year:

2025

Background Low serum albumin levels indicate frailty and are strong predictors of poor prognosis after mitral transcatheter edge‐to‐edge repair (M‐TEER); however, albumin levels are expected to improve in response to treatment for mitral regurgitation. No reports have elucidated the clinical effects of albumin changes after M‐TEER. Thus, we aimed to explore the association between early albumin changes and clinical outcomes after M‐TEER and to identify the associated factors. Methods Data from 2695 patients enrolled in a Japanese multicenter registry whose serum albumin levels were measured before and 1 month after undergoing M‐TEER were retrospectively reviewed. Changes in albumin (Δ‐albumin) were calculated and divided into 2 groups, namely improved albumin (Δ‐albumin >0) and worsening albumin (Δ‐albumin ≤0) groups. The incidence, predictors, and clinical outcomes associated with early albumin changes were investigated. Results After M‐TEER, albumin levels improved in 56.1% of the patients (n=1512). The independent predictors of worsening Δ‐albumin comprised old age, acute procedure success not achieved, higher Clinical Frailty Scale, higher hemoglobin, impaired renal function, and preprocedural higher albumin levels (all P <0.05). Improved Δ‐albumin was independently associated with reduced all‐cause mortality after M‐TEER (hazard ratio [HR], 0.62 [95% CI, 0.52–0.75], P <0.001). Additionally, improved Δ‐albumin was associated with a lower competing risk of heart failure hospitalization (HR, 0.78 [95% CI, 0.64–0.94], P =0.01). Conclusions Early improvement in Δ‐albumin may serve as a measure of procedural benefits and a surrogate marker for predicting clinical outcomes after M‐TEER.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (12)

Kiyoshi Hibi

-

JAPAN
View details

Toshiro Shinke

Professor

Showa University School of Medicine

JAPAN
View details

Yuji Ikari

Director / Professor

Tohoku University Hospital

JAPAN
View details

Masato Nakamura

Professor

Toho University

JAPAN
View details

Kentaro Hayashida

Keio University School of Medicine

JAPAN
View details

Ken Kozuma

-

JAPAN
View details

Hiroshi Ueno

University of Toyama

JAPAN
View details

Taishi Yonetsu

Associate Professor

Tokyo Medical and Dental University

JAPAN
View details

Yasuhiro Honda

Professor of Medicine

Stanford University School of Medicine

UNITED STATES
View details

Junya Ako

Kitasato University

JAPAN
View details

Yusuke Watanabe

Teikyo University Hospital

JAPAN
View details

Shuhei Tanaka

University of Toyama

JAPAN
View details